title: Hexamethylmelamine chemotherapy for disseminated endometrial cancer.
abstract: To evaluate the role of hexamethylmelamine (HMM) in the treatment of endometrial cancer, 20 women with metastatic or recurrent endometrial carcinoma received HMM orally at a dose of 8 mg/kg/day. Six patients (30%) showed a partial response, with a median duration of response of 3.5 months and a range of 1 to 7 months. Two patients responded to HMM as a second-line agent following previous treatment with nonhormonal chemotherapy. There were no complete responses. The major toxicities noted with HMM therapy were nausea, vomiting, and neurotoxicity. In 6 patients (30%), therapy with HMM was discontinued because of toxicity. Although HMM is active against endometrial cancer when given at a dose of 8 mg/kg/day, it appears to have limited usefulness because toxicity precludes its prolonged administration.
mesh_terms: D000368:Aged; D006585:Altretamine / Q000627:therapeutic use* / Q000633:toxicity; D001259:Ataxia / Q000139:chemically induced; D003221:Confusion / Q000139:chemically induced; D005260:Female; D006801:Humans; D008875:Middle Aged; D009123:Muscle Hypotonia / Q000139:chemically induced; D009325:Nausea / Q000139:chemically induced; D012026:Reflex, Stretch / Q000187:drug effects; D014227:Triazines / Q000627:therapeutic use*; D014594:Uterine Neoplasms / Q000188:drug therapy*; D014839:Vomiting / Q000139:chemically induced
chemical_list: D014227:Triazines; D006585:Altretamine